Scientists crack the code to tamoxifen resistance

Scientists have discovered the molecular basis for tamoxifen response in breast cancer cells – and the reason why some women can develop resistance to the treatment, according to a study published in Nature this week.
Tamoxifen is given to most women for five years after they are first diagnosed with breast cancer to help prevent the disease from coming back but some women develop resistance to the treatment after time, meaning their cancer is more likely to return.
Researchers at the Cancer Research UK and University of Cambridge Cambridge Research Institute have discovered for the first time the mechanism by which the breast cancer therapy tamoxifen operates. It switches off a breast cancer gene ErbB2 via a protein called Pax2. Pax2 acts as a ‘switch’ to keep ErbB2 switched off. Tamoxifen resistance occurs when ErbB2 remains switched on.
Previously it was known that tamoxifen worked by blocking oestrogen from causing unchecked cell growth in breast cancer by switching certain genes on but the mechanism by which this occurred was unknown.
Lead author, Dr Jason Carroll based at the Cambridge Research Institute said: “We knew that women developed resistance to tamoxifen but previously our understanding of why this occurred could be compared with trying to fix a broken car without knowing how the engine worked. Now we understand how all the engine parts operate and we can try to think about ways to make repairs.
“We have discovered that for tamoxifen to work it has to block the gene ErbB2 and it does this by using a control switch that is hidden in the background of the genome, within the ErbB2 gene itself. In order for tamoxifen to be effective, this switch must be held in the off position by Pax2. Now we understand how women can develop tamoxifen resistance.”
The production of oestrogen can cause breast cancer cells to grow and divide but tamoxifen prevents oestrogen from causing breast cancer cells to grow, helping to lower the risk of the disease returning. Most women have breast cancers that are stimulated to grow by oestrogen but not all.
Breast cancer is the most common cancer in women in the UK. More than 45,500 women are diagnosed with the disease each year – 125 women a day, and the disease causes almost 12,500 deaths each year. Eight in 10 cases of breast cancer are diagnosed in women over the age of 50.
Related News
See all news-
Scientists to Shine a Light on Cancer Research at Inspirational Night Walk
10th October 2025
Dr Shalini Rao, a Senior Research Associate at the Cancer Research UK Cambridge Institute, will join postgraduate students Marleen Wolke and Josephine Greenall-Ota for the Shine Night Walk on Saturday, 18 October.
Find out more -
Prof Greg Hannon shortlisted for prestigious Cancer Grand Challenge
24th September 2025
The shortlist of 12 multidisciplinary, global teams is now competing for up to £20m each, with the aim of delivering breakthroughs that no single researcher, lab, institute or country could achieve alone.
Find out more -
Future scientists join our second Cambridge LaunchPad project day
18th August 2025
Students from Thomas Clarkson Academy in Wisbech joined us for a unique opportunity to experience the world of cancer research first-hand.
Find out more